Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Reader Login  

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 254 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1994| April-June  | Volume 5 | Issue 2  
    Online since June 17, 2008

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
PRACTICAL PROCEDURE
Acute Peritoneal Dialysis Using Stylet Catheter
T Timothy Paul, KS Ramprasad
April-June 1994, 5(2):184-189
PMID:18583831
  5,417 350 -
ORIGINAL ARTICLES
Intravenous Iron Saccharate in Hemodialysis Patients Receiving r-HuEPO
Abdul-Kareem M Al-Momen, Sameer O Huraib, Ahmed H Mitwalli, Jamal Al-Wakeel, Mohammad J.M.S Al-Yamani, Hassan Abu-Aisha, Riyad Said
April-June 1994, 5(2):168-172
PMID:18583828
A study was undertaken to evaluate the safety and efficacy of iron saccharate in regular haemodialysis (HD) patients receiving r-HuEPO. A total of 109 patients (57 males, 52 females, mean age 34.1 + 11.7 years) were included in the study, 64 of whom were iron deficient. The patients were divided into two groups. Group I (n = 58) received high dose iron saccharate (500 mg), intravenously (i.v.) (1-2 doses), and Group II (n = 51) received low dose iron saccharate (100 mg), i.v., thrice per week (5-10 doses). Results at four weeks showed a significant increment in hemoglobin (Hb), hematocrit (Hct), and serum ferritin in both groups. Two patients developed headache, fever and urticaria, and three patients developed fever in group I. None of the patients in group II developed any adverse reaction. Intravenous iron supplementation with iron saccharate in HD patients showing poor response to r-HuEPO, produced satisfactory Hct levels without major side effects and without the need to increase the dose of r-HuEPO. Commonly observed side effects were not seen with the low dose regimen.
  4,014 279 -
SPECIAL ARTICLE
Uniform Requirements for Manuscripts Submitted to Biomedical Journals
International Committee of Medical Journal Editors
April-June 1994, 5(2):147-153
PMID:18583823
  3,569 366 -
REVIEW ARTICLE
Comparison of CAPD and CCPD in Children and their Limitations
J Williamson Balfe
April-June 1994, 5(2):173-178
PMID:18583829
Soon after its introduction, continuous ambulatory peritoneal dialysis (CAPD) became the choice mode of dialysis treatment for small children. With the advent of automated machines, continuous cycling peritoneal dialysis (CCPD) is now finding more favor in many centers. Initial cost of CCPD is higher due to the need for automated machines, but puts much less strain on the family. However, there is evidence that biochemical control is better with CAPD. Growth and nutrition in both groups are found to be similar. CCPD may have advantages over CAPD with regard to infection, since the former has fewer disconnections. The same is also true with regard to hernias and leaks. Some patients still prefer CAPD, since it allows more freedom in life style compared to CCPD.
  3,113 253 -
EDITORIALS
CAPD: Is it a Viable Mode of Renal Replacement Therapy in Saudi Arabia?
Hassan Abu-Aisha, T Timothy Paul
April-June 1994, 5(2):154-156
PMID:18583824
  2,671 176 -
COUNTRY REPORT
An Overview of Renal Replacement Therapy in Algeria
Hottman Salah
April-June 1994, 5(2):190-192
PMID:18583832
  2,610 233 -
ORIGINAL ARTICLES
Can Uremia and Hemodialysis Affect Plasma Levels of Circulating TNF-α
Mohsen Mohammed Hussein Al-Koussi, Mohammed Ali Tohamy, Inas Ahmed Reda El-Kareimy, NAH Kamel, Lubna Al-Menawy, Iftikhar Ahmed Sheikh, Faissal A.M Shaheen
April-June 1994, 5(2):163-167
PMID:18583827
It is well known that uremia is associated with increased susceptibility to infection. In addition, patients on haemodialysis (HD) experience a variety of dialysis associated complications, both acute and chronic, many of them having features similar to acute phase response. Immunoregulatory cytokines such as tumor necrosis factor-a (TNF-a) have been implicated in the pathogenesis of immunological as well as inflammatory diseases. Thus, TNF-a levels could be expected to be high in uremic patients as well as in HD patients. We investigated the plasma levels of TNF-a in 17 patients with renal failure, seven patients with chronic renal failure (CRF) before commencement of HD and 10 patients maintained on regular HD. Eight age matched healthy subjects were studied as normal control. All CRF patients, who were not yet on dialysis, had high plasma levels of TNF-a (mean + SD 71.33 + 33.25 pg/ml). Out of the HD group, TNF-a plasma levels were not detectable in five patients and in the remaining five, TNF-a plasma level (mean + SD 21.06 + 7.72) were comparable to the normal controls (mean + SD 21 + 7.87). Our findings suggest that factors related to uremia, but not to HD, are responsible for high TNF-a plasma levels in these patients and that, HD probably has a beneficial effect by removal and/or neutralising of uremic toxins.
  1,733 247 -
CASE REPORT
Chronic Tubulo-interstitial Nephropathy with Hepatic Involvement in Children
Abdullah A Al-Salloum
April-June 1994, 5(2):179-183
PMID:18583830
The clinical, biochemical and histological data are reported in a female infant with rapidly progressive renal failure, hepatosplenomegaly and death at the age of 2 years. This case represents another example of the newly described entity "chronic tubulo­interstitial nephritis with hepatic involvement" and the only reported case of this kind from this part of the world.
  1,789 178 -
EDITORIALS
Hepatitis C Virus Infection in Haemodialysis Patients in Saudi Arabia
R Padmanabhan
April-June 1994, 5(2):157-158
PMID:18583825
  1,687 184 -
Incidence and Causes of Long-term Renal Allograft Loss
JD Briggs
April-June 1994, 5(2):159-162
PMID:18583826
The dramatic improvement observed in the short term of graft survival following the introduction of cyclosporine A, led many transplant doctors to think that long term patient and graft survival will also show similar improvement. This has not been the case and after the first year, the survival curves run parallel to those observed during the earlier years. In an analysis of 446 patients whose grafts functioned for more than 1 year, chronic rejection alone accounted for more than 80% cases of graft loss among the 53 cases with progressive graft failure. Previous acute rejection was found to be an important predisposing factor to chronic rejection in these cases. Since chronic rejection is still an untreatable condition, all efforts should be made to prevent acute rejection in the hope that this may lessen the likelihood of late graft failure.
  1,368 179 -
LETTERS TO THE EDITOR
The Kidney and HIV Infection
Ali Hijazi
April-June 1994, 5(2):200-202
PMID:18583833
  1,219 145 -
The authors reply
Y Boobes
April-June 1994, 5(2):202-202
  1,169 130 -
Renal Transplantation in Ghaem Hospital Medical School
Ali Shamsa, Ahmad Saghebi
April-June 1994, 5(2):203-203
PMID:18583834
  1,000 144 -
  My Preferences